<DOC>
	<DOCNO>NCT01721694</DOCNO>
	<brief_summary>To evaluate efficacy safety fix combination azithromycin 1.5 % + 0.5 % Loteprednol eye drop treatment ocular inflammation infection associate bacterial blepharitis / keratitis / conjunctivitis compare individual administration azithromycin 1.5 % 0.5 % Loteprednol ( separately ) .</brief_summary>
	<brief_title>Antibiotic Steroid Combination Compared With Individual Administration Treatment Ocular Inflammation Infection</brief_title>
	<detailed_description>Estimated admitted total approximately 60 patient show blepharitis / keratitis / conjunctivitis : 30 patient assign group Azithromycin 1.5 % /Loteprednol 0.5 % Eye Drops ( fix combination ) + placebo 30 patient assign group Azithromycin 1.5 % + 0.5 % Loteprednol ( separately )</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Blepharitis</mesh_term>
	<mesh_term>Keratitis</mesh_term>
	<mesh_term>Conjunctivitis , Bacterial</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Patients male female , race age minimum 18 year . Blepharitis provide diagnostic / keratitis / conjunctivitis without bacterial involvement corneal biomicroscopy , positive stain corneal fluorescein also provide composite score â‰¥ 2 : bulbar conjunctival hyperemia , eyelid conjunctiva , secretion / exudate conjunctival erythema flake eyelid / eyelid crust least one eye ( eye ) Day 1 visit Intraocular hypertension uncontrolled glaucoma . Use contact lens study . Capacity unilateral visual . Suspected fungal infection , viral ( eg , herpes simplex epithelial , dendritic keratitis ) Acanthamoeba , disease use corticosteroid contraindicate . Use topical ophthalmic medication preserve study participation . Not allow eyedrop preserve ( eg artificial tear ) . Use antibacterial agent oral topical ophthalmic 72 hour prior study entry . Use systemic steroid within 14 day prior study entry . Ophthalmic topical steroid nonsteroidal antiinflammatory drug ( NSAIDs ) , one week admission study . Will allow use medication study participation . Will allow use nasal steroid study . Will allow use inhaled steroid aid inhaler . Will allow steroid dermal topic . Use nonsteroidal antiinflammatory drug ( NSAIDs ) systemic 24 hour prior study entry time study , unless patient treatment regimen stable ( necessary ) least 2 month Admission therapy continue throughout study . Any disturbance ocular systemic disease , complicate factor structural abnormality affect conduct outcome study negative way represent undue risk patient safety , accord opinion investigator . Any current immunosuppressive disorder ( eg , HIVpositive ) , immunosuppressive therapy ( include chemotherapy ) . Known allergy suspect allergy hypersensitivity fluoroquinolones , steroid component study drug ; Pregnant lactating . ( Women childbearing age may admit use contraception submit urine pregnancy test negative ) ; Any patient family member participates study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>bacterial ocular inflammation</keyword>
	<keyword>blepharitis</keyword>
	<keyword>keratitis</keyword>
	<keyword>conjunctivitis</keyword>
</DOC>